Resources from the same session
Single agent activity of DS-8201a, a HER2-targeting antibody-drug conjugate, in breast cancer patients previously treated with T-DM1: Phase 1 dose escalation
Presenter: Kenji Tamura
Session: Breast cancer, metastatic
Resources:
Abstract
Phase II randomised clinical study of metformin plus chemotherapy vs chemotherapy alone in HER2 negative metastatic breast cancer: final results of the MYME trial
Presenter: Alessandra Gennari
Session: Breast cancer, metastatic
Resources:
Abstract
Invited discussant abstracts LBA16, LBA17 and 224PD
Presenter: Cristina Saura
Session: Breast cancer, metastatic
Resources:
Slides
Webcast
Invited discussant abstracts 228PD, 229PD, 230PD and 231PD
Presenter: Luis Costa
Session: Breast cancer, metastatic
Resources:
Slides
Webcast
Impact of palbociclib plus letrozole on health related quality of life (HRQOL) compared with letrozole alone in treatment naïve postmenopausal patients with ER+ HER2- metastatic breast cancer (MBC): results from PALOMA-2
Presenter: Hope Rugo
Session: Breast cancer, metastatic
Resources:
Abstract
Heritage, a phase III safety and efficacy trial of the proposed trastuzumab biosimilar, Myl-1401O vs trastuzumab
Presenter: Hope Rugo
Session: Breast cancer, metastatic
Resources:
Abstract
First line hormone therapy vs chemotherapy for HR+ HER2- metastatic breast cancer in the phase III STIC CTC trial: clinical choice and validity of CTC count
Presenter: Francois-Clement Bidard
Session: Breast cancer, metastatic
Resources:
Abstract
FALCON: A phase III randomised trial of fulvestrant 500 mg vs. anastrozole for hormone receptor-positive advanced breast cancer
Presenter: Matthew Ellis
Session: Breast cancer, metastatic
Resources:
Abstract
Everolimus use in breast cancer patients: a population-based study
Presenter: Mariana Chavez-Macgregor
Session: Breast cancer, metastatic
Resources:
Abstract
Efficacy and safety of BCD-022, trastuzumab biosimilar candidate, compared to herceptin: Results of international multicenter randomized double blind study in patients with HER2+ mBC
Presenter: Maria Shustova
Session: Breast cancer, metastatic
Resources:
Abstract
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
-
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and can only be disabled by changing your browser preferences.